{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:12:48Z","timestamp":1775725968527,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001729","name":"Stiftelsen f\u00f6r\u00a0Strategisk Forskning","doi-asserted-by":"publisher","award":["ID21-0048"],"award-info":[{"award-number":["ID21-0048"]}],"id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04880-x","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:35:00Z","timestamp":1774568100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated FHIT and IDH2 biomarker profiling predicts lethal sensitivity to DCPS inhibition in Acute Myeloid Leukemia and Myelodysplastic syndrome"],"prefix":"10.1007","volume":"17","author":[{"given":"Francesca","family":"Grassi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Bast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhurendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Tobiasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Walfridsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"de Milito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"issue":"5","key":"4880_CR1","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100(5):860\u201391.","journal-title":"Am J Hematol"},{"issue":"26","key":"4880_CR2","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1182\/blood.2023020078","volume":"142","author":"R Hasserjian","year":"2023","unstructured":"Hasserjian R, Geming U, Malcovati L. Diagnosis and classification of myelodysplastic syndromes. Blood. 2023;142(26):2247\u201357.","journal-title":"Blood"},{"issue":"19","key":"4880_CR3","first-page":"2125","volume":"136","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;136(19):2125\u201332.","journal-title":"Blood"},{"issue":"3","key":"4880_CR4","first-page":"38","volume":"103","author":"A Pelcovits","year":"2020","unstructured":"Pelcovits A, Niroula R. Acute myeloid leukemia: a review. Rhode Island Med J. 2020;103(3):38\u201340.","journal-title":"Rhode Island Med J"},{"key":"4880_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jare.2025.05.038","volume":"80","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Lu Y, Mai L, Wen Z, Dai M, Xu S, et al. Dynamic heterogeneity towards drug resistance in AML cells is primarily driven by epigenomic mechanism unveiled by multi-omics analysis. J Adv Res. 2025;80:487\u2013501.","journal-title":"J Adv Res"},{"issue":"9","key":"4880_CR6","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.3390\/cancers14092182","volume":"14","author":"RH Desai","year":"2022","unstructured":"Desai RH, Zandvakili N, Bohlander SK. Dissecting the genetic and non-genetic heterogeneity of acute myeloid leukemia using next-generation sequencing and in vivo models. Cancers. 2022;14(9):2182.","journal-title":"Cancers"},{"issue":"3","key":"4880_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ccell.2018.01.012","volume":"33","author":"T Yamauchi","year":"2018","unstructured":"Yamauchi T, Masuda T, Canver MC, Seiler M, Semba Y, Shboul M, et al. Genome-wide CRISPR-Cas9 screen identifies leukemia-specific dependence on a Pre-mRNA metabolic pathway regulated by DCPS. Cancer Cell. 2018;33(3):386\u2013400.","journal-title":"Cancer Cell"},{"issue":"7","key":"4880_CR8","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1021\/acschembio.2c00145","volume":"17","author":"JC Swartzel","year":"2022","unstructured":"Swartzel JC, Bond MJ, Pintado-Urbanc AP, Daftary M, Krone MW, Douglas T, et al. Targeted degradation of mRNA decapping enzyme DcpS by a VHL-recruiting PROTAC. ACS Chem Biol. 2022;17(7):1789\u201398.","journal-title":"ACS Chem Biol"},{"issue":"8","key":"4880_CR9","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1038\/s41375-025-02661-z","volume":"39","author":"F Grassi","year":"2025","unstructured":"Grassi F, Singh M, Moussaud S, Rodriguez GV, Ali Z, Janssen K, et al. DCPS is a synthetic lethal therapeutic target in acute myeloid leukemia expressing low levels of FHIT. Leukemia. 2025;39(8):2021\u20135.","journal-title":"Leukemia"},{"issue":"8","key":"4880_CR10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/sj.leu.2403805","volume":"19","author":"M Iwai","year":"2005","unstructured":"Iwai M, Kiyoi H, Ozeki K, Kinoshita T, Emi N, Ohno R, et al. Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 2005;19(8):1367\u201375.","journal-title":"Leukemia"},{"key":"4880_CR11","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-03-2387","volume":"64","author":"S Zheng","year":"2004","unstructured":"Zheng S, Ma X, Zhang L, Gunn L, Smith MT, Wiemels JL, et al. Hypermethylation of the 5 CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia. Cancer Res. 2004;64:2000\u20136.","journal-title":"Cancer Res"},{"issue":"17","key":"4880_CR12","doi-asserted-by":"publisher","first-page":"28812","DOI":"10.18632\/oncotarget.15807","volume":"8","author":"M Tobiasson","year":"2017","unstructured":"Tobiasson M, Abdulkadir H, Lennartsson A, Katayama S, Marabita F, De Paepe A, et al. Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive\/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease. Oncotarget. 2017;8(17):28812\u201325.","journal-title":"Oncotarget"},{"issue":"2","key":"4880_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273\u201386.","journal-title":"Biostatistics"},{"issue":"2","key":"4880_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1586\/erm.10.120","volume":"11","author":"M Buyse","year":"2011","unstructured":"Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, De Gramont A. Integrating biomarkers in clinical trials. Expert Rev Mol Diagn. 2011;11(2):171\u201382.","journal-title":"Expert Rev Mol Diagn"},{"issue":"6","key":"4880_CR15","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1158\/1078-0432.CCR-09-2167","volume":"16","author":"JE Dancey","year":"2010","unstructured":"Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010;16(6):1745\u201355.","journal-title":"Clin Cancer Res"},{"issue":"01","key":"4880_CR16","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.26502\/acbr.50170321","volume":"07","author":"G Silberberg","year":"2023","unstructured":"Silberberg G, Walling B, Wesa A, Audia A, Sloma I, Zeng Y, et al. Pharmaco-pheno-multiomic integration reveals biomarker profiles and therapeutic response prediction models in leukemia and ovarian cancer. Arch Clin Biomed Res. 2023;07(01):2022\u201306.","journal-title":"Arch Clin Biomed Res"},{"issue":"2","key":"4880_CR17","doi-asserted-by":"publisher","first-page":"e70083","DOI":"10.1002\/hem3.70083","volume":"9","author":"U Platzbecker","year":"2025","unstructured":"Platzbecker U, Larson RA, Gurbuxani S. Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: divergent nomenclature converges on common therapies. HemaSphere. 2025;9(2):e70083.","journal-title":"HemaSphere"},{"issue":"3","key":"4880_CR18","doi-asserted-by":"publisher","first-page":"e438662","DOI":"10.1200\/EDBK_438662","volume":"44","author":"Y Abaza","year":"2024","unstructured":"Abaza Y, McMahon C, Garcia JS. Advancements and challenges in the treatment of AML. Am Soc Clin Oncol Educ Book. 2024;44(3):e438662.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"24","key":"4880_CR19","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1200\/JCO.2009.22.3701","volume":"27","author":"SJ Mandrekar","year":"2009","unstructured":"Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol. 2009;27(24):4027\u201334.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4880_CR20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41584-018-0005-9","volume":"14","author":"VB Kraus","year":"2018","unstructured":"Kraus VB. Biomarkers as drug development tools: discovery, validation, qualification and use. Nat Rev Rheumatol. 2018;14(6):354\u201362.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"4880_CR21","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/ajh.26572","volume":"97","author":"K Kim","year":"2022","unstructured":"Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, et al. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol. 2022;97(7):885\u201394.","journal-title":"Am J Hematol"},{"issue":"11","key":"4880_CR22","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1182\/blood.V110.11.4368.4368","volume":"110","author":"AM Quessar","year":"2007","unstructured":"Quessar AM, Khoubila NR, Ribeiro RCU, Rachid MA, Zafad SD, Harif MM, et al. Hydroxyurea in the early management of acute myeloid leukemia and hyperleukocytosis. Blood. 2007;110(11):4368\u20134368.","journal-title":"Blood"},{"issue":"23","key":"4880_CR23","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S0960-9822(01)00572-3","volume":"11","author":"MN Boddy","year":"2001","unstructured":"Boddy MN, Russell P. Primer DNA replication checkpoint. Curr Biol. 2001;11(23):953\u20136.","journal-title":"Curr Biol"},{"key":"4880_CR24","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/genes12071096","volume":"12","author":"MW Musia\u0142ek","year":"2021","unstructured":"Musia\u0142ek MW, Rybaczek D. Hydroxyurea-the good, the bad and the ugly. Genes. 2021;12:1096.","journal-title":"Genes"},{"issue":"1","key":"4880_CR25","first-page":"117","volume":"110","author":"H Komic","year":"2025","unstructured":"Komic H, Nilsson MS, Wennstr\u00f6m L, Bandaru TS, Jaako P, Hellstrand K, et al. Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia. Haematologica. 2025;110(1):117\u201328.","journal-title":"Haematologica"},{"issue":"1","key":"4880_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nm.4439","volume":"24","author":"H Bolouri","year":"2018","unstructured":"Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24(1):103\u201312.","journal-title":"Nat Med"},{"issue":"8","key":"4880_CR27","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-15-1015","volume":"76","author":"JE Farrar","year":"2016","unstructured":"Farrar JE, Schuback HL, Ries RE, Wai D, Hampton OA, Trevino LR, et al. Genomic profiling of pediatric acute myeloid leukemia reveals a changing mutational landscape from disease diagnosis to relapse. Cancer Res. 2016;76(8):2197\u2013205.","journal-title":"Cancer Res"},{"issue":"10","key":"4880_CR28","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.leukres.2008.02.008","volume":"32","author":"J Lin","year":"2008","unstructured":"Lin J, Yao DM, Qian J, Wang YL, Han LX, Jiang YW, et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leuk Res. 2008;32(10):1541\u20135.","journal-title":"Leuk Res"},{"issue":"2","key":"4880_CR29","first-page":"339","volume":"110","author":"N Kr\u00f6ger","year":"2025","unstructured":"Kr\u00f6ger N. Treatment of high-risk myelodysplastic syndromes. Haematologica. 2025;110(2):339\u201349.","journal-title":"Haematologica"},{"issue":"6","key":"4880_CR30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1177\/2040620712464882","volume":"3","author":"C Khan","year":"2012","unstructured":"Khan C, Pathe N, Fazal S, Lister J, Rossetti JM. Azacitidine in the management of patients with myelodysplastic syndromes. Ther Adv Hematol. 2012;3(6):355\u201373.","journal-title":"Ther Adv Hematol"},{"key":"4880_CR31","doi-asserted-by":"crossref","unstructured":"Jiang C, Beji C, Zebachi S, Hayek GY, Cetinyurek-Yavuz A, Fayyad MBN et al. Decision-making criteria and methods for initiating late-stage clinical trials in drug development from a multi-stakeholder perspective: a scoping review. Clin Pharmacol Ther. 2025. 117(4):978\u201388.","DOI":"10.1002\/cpt.3566"},{"key":"4880_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1201\/9780203911235","volume-title":"Biomarkers in clinical drug development","author":"JC Bloom","year":"2003","unstructured":"Bloom JC, Dean RA. Biomarkers in clinical drug development. Marcel Dekker: New York; 2003. p. 295."},{"issue":"21","key":"4880_CR33","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, Dinardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144(21):2169\u201373.","journal-title":"Blood"},{"issue":"12","key":"4880_CR34","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1182\/blood.2024024011","volume":"145","author":"SD Green","year":"2025","unstructured":"Green SD, Wang ES. How I treat secondary acute myeloid leukemia. Blood. 2025;145(12):1260\u201372.","journal-title":"Blood"},{"issue":"4","key":"4880_CR35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11912-024-01503-y","volume":"26","author":"M Wysota","year":"2024","unstructured":"Wysota M, Konopleva M, Mitchell S. Novel therapeutic targets in acute myeloid leukemia (AML). Curr Oncol Rep. 2024;26(4):409\u201320.","journal-title":"Curr Oncol Rep"},{"issue":"23","key":"4880_CR36","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"key":"4880_CR37","doi-asserted-by":"crossref","unstructured":"Dinardo CD, Cortes JE. Mutations in AML: prognostic and therapeutic implications. Hematology. 2016;20161:348\u201355.","DOI":"10.1182\/asheducation-2016.1.348"},{"issue":"8","key":"4880_CR38","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/ajh.24072","volume":"90","author":"CD Dinardo","year":"2015","unstructured":"Dinardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732\u20136.","journal-title":"Am J Hematol"},{"issue":"6","key":"4880_CR39","doi-asserted-by":"publisher","first-page":"E583","DOI":"10.1097\/HS9.0000000000000583","volume":"5","author":"BJ Wouters","year":"2021","unstructured":"Wouters BJ. Targeting IDH1 and IDH2 mutations in acute myeloid leukemia: emerging options and pending questions. Hemasphere. 2021;5(6):E583.","journal-title":"Hemasphere"},{"issue":"20","key":"4880_CR40","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1158\/1078-0432.CCR-18-0536","volume":"24","author":"ML Amaya","year":"2018","unstructured":"Amaya ML, Pollyea DA. Targeting the IDH2 pathway in acute myeloid leukemia. Clin Cancer Res. 2018;24(20):4931\u20136.","journal-title":"Clin Cancer Res"},{"key":"4880_CR41","unstructured":"U.S. Food and Drug Administration. Guidance for industry expedited programs for serious conditions-drugs and biologics guidance for industry. 2014. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/expedited-programs-serious-conditions-drugs-and-biologics."}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04880-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04880-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04880-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T08:22:46Z","timestamp":1775722966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04880-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4880"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04880-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MDS methylation data were obtained from Tobiasson et al., Oncotarget 2017; 8 [17]:28812\u201328825, which conducted research in accordance with the Declaration of Helsinki, approved by the Ethical committee at Karolinska Institutet, Sweden (Dnr 2010\/427 \u2212 31\/1). Primary AML data were obtained from Champions Oncology, which conducted research under the approval of the University of Pennsylvania\u2019s Institutional Review Board (IRB protocol 703185). This study did not involve direct recruitment or enrollment of human participants. All human-derived data were obtained from previously published studies or commercially available de-identified sources. Informed consent was obtained from all participants by the original investigators in each source study: Tobiasson et al. (Oncotarget, 2017) for MDS data, and Champions Oncology under IRB protocol 703185 for primary AML data. Publicly available AML datasets accessed via cBioPortal contain de-identified data for which informed consent was obtained from all participants by the original study investigators.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study does not contain identifiable individual patient data. All data were obtained from previously published or commercially available de-identified sources.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"F.G., L.B., M.S., A.D.M., M.A. are employees of Sprint Bioscience AB. A.H and J.W. are employees of NeoTargets AB. A.D.M., M.A. and A.H. are shareholders in Sprint Bioscience AB. M.T. declares no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"550"}}